The promising feed additive can potentially stabilize the gut of piglets and reduce the severity of post-weaning diarrhea (PWD) which is one of the biggest challenges in the global swine industry.
“We are very excited to join this partnership with Bactolife. Together, we will be able to develop innovative biosolutions that can stabilize the gut of piglets, increase productivity, and significantly reduce the use of antibiotic use among pigs,” says Sofie Louise Trads, Director, Animal Health at Novozymes.
PWD is caused by E. coli infections in newly weaned pigs and globally, it is estimated to lead to a loss of production of US$1-2 billion per year.
Additionally, PWD is considered the main driver for antibiotic use in weaner pigs. In Denmark alone, antibiotic consumption among weaners constitutes 49% of the total use of antibiotics in pigs, according to Danish Integrated Antimicrobial Resistance Monitoring and Research Program (DANMAP).
According to the company’s statement, the product candidate, Ablacto+, is a functional feed additive which consists of binding proteins with a specific mode of action.
Binding proteins are science-backed, versatile ingredients that significantly reduce the risk of gastrointestinal infections including PWD.
“This is a major validation of Bactolife’s technology platform, and with a strong commercial partnership in the Animal Health space like Novozymes, we believe there is significant business potential for both parties,” says Sebastian Søderberg, CEO at Bactolife.
Novozymes and Bactolife believe that their new biosolution with its novel mode of action can be a game changer in reducing antibiotic consumption in pigs and thereby reducing the risk of antibiotic resistance development in both pigs and humans.
“Since we started Bactolife, Ablacto+ has been leading the way for our technology platform, validating the impact that highly specific binding proteins can have on complex problems, such as PWD. Ablacto+ will support animal welfare and global health as antibiotics use is reduced and animals remain healthy,” says Sandra Wingaard Thrane, CSO at Bactolife.
ABLACTO+ has already shown promising results in large-scale swine trials, and Novozymes and Bactolife will now collaborate to finalize the product development and subsequently commercialize the Ablacto+ product. Novozymes will develop and produce the final product and has the global exclusive marketing and sales responsibility.
Although this product has already proved successful in large scale swine trials, Ablacto+ is expected to be launched in 2026.